The Economic Burden of Head and Neck Cancers in Denmark

Jens Olsen, Tine Rikke Jørgensen, Niclas Rubek

Rigshospitalet, Copenhagen, Denmark.
Sanofi Pasteur MSD ApS, Kongens Lyngby, Denmark.
University of Southern Denmark, Odense C, Denmark.

DOI: 10.4236/ijohns.2013.23024                

Abstract

Introduction: The incidence of head and neck cancers has increased markedly over the last decade. A Danish study of the costs of head and neck cancers has not been undertaken. Such studies have again become relevant due to the development of the HPV vaccines, as some cases are attributable to high-risk HPV 16 or 18. The objective of study was to estimate the incidence of head and neck cancers and their health care costs. Methods: Data on incidence and health care use related to head and neck cancer were obtained from Danish health care registers. New cancer patients were identified in the Danish National Cancer Register. Resource use per year in the hospital sector was estimated using data from the National Patient Register applying charges as cost estimates. Health care consumption by cancer patients was compared with that by an age- and sex-matched cohort without cancer. Results: We found that nearly 1000 new cases of oral cavity, oropharyngeal, hypopharyngeal and laryngeal cancer are diagnosed annually. In total the cost of these cancers to the Danish hospital sector constituted 31.6 million Euros per year, with the majority of costs (74%) occurring in men. The total costs associated with HPV16/18-related head and neck cancers were estimated to be 6.1 million Euros per year. Conclusion: This study provides the first Danish estimates of the costs associated with non-cervical and non-genital HPV-related cancers based on very reliable, individual-based data. It is expected that the current HPV vaccination programme will reduce this burden.

Keywords

Head and Neck Cancer; Cost-of-Illness; Human Papilloma Virus (HPV) Infections

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	National Board of Health, “The Cancer Register 2010 [Tal og Analyse: Cancerregisteret 2010],” National Board of Health, 2011.
[2]	A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward and D. Forman, “Global Cancer Statistics,” CA: Cancer Journal for Clinicians, Vol. 61, No. 2, 2011, pp. 69-90. doi:10.3322/caac.20107
[3]	J. L. St Guily, I. Borget, A. Vainchtock, V. Remy and C. Takizawa, “Head and Neck Cancers in France: An Analysis of the Hospital Medical Information System (PMSI) Database,” Head & Neck Oncology, Vol. 2, 2010, p. 22. doi:10.1186/1758-3284-2-22
[4]	E. M. Sturgis and P. M. Cinciripini, “Trends in Head and Neck Cancer Incidence in Relation to Smoking Prevalence: An Emerging Epidemic of Human Papillomavirus-Associated Cancers?” Cancer, Vol. 110, No. 7, 2007, pp. 1429-1435. doi:10.1002/cncr.22963
[5]	M. Hashibe, P. Brennan, S. C. Chuang, et al., “Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 18, No. 2, 2009, pp. 541-550. doi:10.1158/1055-9965.EPI-08-0347
[6]	M. B. Gillespie, S. Rubinchik, B. Hoel and N. Sutkowski, “Human Papillomavirus and Oropharyngeal Cancer: What You Need to Know in 2009,” Current Treatment Options in Oncology, Vol. 10, No. 5-6, 2009, pp. 296-307. doi:10.1007/s11864-009-0113-5
[7]	S. Marur, G. D’Souza, W. H. Westra and A. A. Forastiere, “HPV-Associated Head and Neck Cancer: A Virus-Related Cancer Epidemic,” The Lancet Oncology, Vol. 11, No. 8, 2010, pp. 781-789. doi:10.1016/S1470-2045(10)70017-6
[8]	M. L. Gillison, G. D’Souza, W. Westra, et al., “Distinct Risk Factor Profiles for Human Papillomavirus Type 16-Positive and Human Papillomavirus Type 16-Negative Head and Neck Cancers,” Journal of the National Cancer Institute, Vol. 100, No. 6, 2008, pp. 407-420. doi:10.1093/jnci/djn025
[9]	P. M. Weinberger, Z. Yu, B. G. Haffty, et al., “Molecular Classification Identifies a Subset of Human Papillomavirus-Associated Oropharyngeal Cancers with Favorable Prognosis,” Journal of Clinical Oncology, Vol. 24, No. 5, 2006, pp. 736-747. doi:10.1200/JCO.2004.00.3335
[10]	R. R. Laborde, V. Novakova, K. D. Olsen, J. L. Kasperbauer, E. J. Moore and D. I. Smith, “Expression Profiles of Viral Responsive Genes in Oral and Oropharyngeal Cancers,” European Journal of Cancer, Vol. 46, No. 6, 2010, pp. 1153-1158. doi:10.1016/j.ejca.2010.01.026
[11]	J. M. Lee, M. Turini, M. F. Botteman, J. M. Stephens and C. L. Pashos, “Economic Burden of Head and Neck Cancer. A Literature Review,” The European Journal of Health Economics, Vol. 5, No. 1, 2004, pp. 70-80. doi:10.1007/s10198-003-0204-3
[12]	I. Borget, L. Abramowitz and P. Mathevet, “Economic Burden of HPV-Related Cancers in France,” Vaccine, Vol. 29, No. 32, 2011, pp. 5245-5249. doi:10.1016/j.vaccine.2011.05.018
[13]	A. R. Kreimer, G. M. Clifford, P. Boyle and S. Franceschi, “Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 14, No. 2, 2005, pp. 467-475. doi:10.1158/1055-9965.EPI-04-0551
[14]	M. Kruse and T. Christiansen, “Register-Based Studies of Healthcare Costs,” Scandinavian Journal of Public Health, Vol. 39, Supplement 7, 2011, pp. 206-209. doi:10.1177/1403494811404277
[15]	H. A. Glick, J. A. Doshi, S. S. Sonnad and D. Polsky, “Analyzing Cost. Economic Evaluation in Clinical Trials,” Oxford University Press, Oxford, 2007.
[16]	J. Lipscomb, M. Ancukiewicz, G. Parmigiani, V. Hasselblad, G. Samsa and D. B. Matchar, “Predicting the Cost of Illness: A Comparison of Alternative Models Applied to Stroke,” Medical Decision Making, Vol. 18, Supplement 2, 1998, pp. S39-S56. doi:10.1177/0272989X9801800207
[17]	D. K. Blough, C. W. Madden and M. C. Hornbrook, “Modeling Risk Using Generalized Linear Models,” Journal of Health Economics, Vol. 18, No. 2, 1999, pp. 153-171. doi:10.1016/S0167-6296(98)00032-0
[18]	M. A. Olsen, A. M. Butler, D. M. Willers, G. A. Gross, B. H. Hamilton and V. J. Fraser, “Attributable Costs of Surgical Site Infection and Endometritis after Low Transverse Cesarean Delivery,” Infection Control and Hospital Epidemiology, Vol. 31, No. 3, 2010, pp. 276-282. doi:10.1086/650755
[19]	Ministry of Health and Prevention, National Board of Health, “[Ministeriet for Sundhed og Forebyggelse, Sundhedsstyrelsen]: Charges 2008—instructions [Takstsystem 2008—Vejledning],” Copenhagen, 2008.
[20]	J. Olsen and M. R. Jepsen, “Human Papillomavirus Transmission and Cost-Effectiveness of Introducing Quadrivalent HPV Vaccination in Denmark,” International Journal of Technology Assessment in Health Care, Vol. 26, No. 2, 2010, pp. 183-191. doi:10.1017/S0266462310000085
[21]	J. Olsen, T. R. Jørgensen, K. Kofoed and H. K. Larsen, “Incidence and Cost of Anal, Penile, Vaginal and Vulva Cancer in Denmark,” BMC Public Health, Vol. 12, 2012, p. 1082. doi:10.1186/1471-2458-12-1082
[22]	D. Hu and S. Goldie, “The Economic Burden of Noncervical Human Papillomavirus Disease in the United States,” American Journal of Obstetrics & Gynecology, Vol. 198, No. 5, 2008, pp. 500-507. doi:10.1016/j.ajog.2008.03.064
[23]	A. Nasman, P. Attner, L. Hammarstedt, et al., “Incidence of Human Papillomavirus (HPV) Positive Tonsillar Carcinoma in Stockholm, Sweden: An Epidemic of Viral-Induced Carcinoma?” International Journal of Cancer, Vol. 125, No. 2, 2009, pp. 362-366. doi:10.1002/ijc.24339
[24]	L. Hammarstedt, D. Lindquist, H. Dahlstrand, et al., “Human Papillomavirus as a Risk Factor for the Increase in Incidence of Tonsillar Cancer,” International Journal of Cancer, Vol. 119, No. 11, 2006, pp. 2620-2623. doi:10.1002/ijc.22177
[25]	S. Syrjanen, “HPV Infections and Tonsillar Carcinoma,” Journal of Clinical Pathology, Vol. 57, No. 5, 2004, pp. 449-455. doi:10.1136/jcp.2003.008656